Holen Sie sich die Stockscreener-App
38.06
1.58%
-0.61
Handel nachbörslich:
37.28
-0.78
-2.05%
Schlusskurs vom Vortag:
$38.67
Offen:
$37.55
24-Stunden-Volumen:
4.53M
Relative Volume:
1.67
Marktkapitalisierung:
$10.25B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
21.50
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
-4.83%
1M Leistung:
-5.06%
6M Leistung:
-3.89%
1J Leistung:
+11.55%
1-Tages-Spanne:
$36.00
$38.41
1-Wochen-Bereich:
$36.00
$40.62
52-Wochen-Spanne:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.06 | 10.41B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis Shares Fall After Guggenheim Downgrade - MarketScreener
EXEL Downgraded to Neutral by Guggenheim on November 3, 2025 | E - GuruFocus
Can Exelixis Inc. stock weather global recessionWeekly Trend Recap & High Accuracy Swing Trade Signals - newser.com
Real time alert setup for Exelixis Inc. performanceM&A Rumor & Weekly High Conviction Ideas - newser.com
Will Exelixis Inc. (EX9) stock rise with strong economyQuarterly Profit Report & Real-Time Volume Analysis Alerts - newser.com
Guggenheim Downgrades Exelixis to Neutral From Buy - MarketScreener
How Exelixis Inc. (EX9) stock reacts to Fed tightening2025 Buyback Activity & Expert Approved Trade Ideas - newser.com
How to escape a deep drawdown in Exelixis Inc.July 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
Exelixis Inc. stock trend forecast2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
How Exelixis Inc. stock trades before earningsIPO Watch & Weekly Watchlist for Hot Stocks - newser.com
Can you recover from losses in Exelixis Inc.Market Growth Summary & Daily Chart Pattern Signals - newser.com
Can Exelixis Inc. stock beat market expectations this quarterJuly 2025 Market Mood & Precise Buy Zone Tips - newser.com
Understanding Exelixis Inc.’s price movement2025 Market Sentiment & Weekly Stock Breakout Alerts - newser.com
How Exelixis Inc. (EX9) stock reacts to new regulationsIndex Update & Free Low Drawdown Momentum Trade Ideas - newser.com
How Exelixis Inc. (EX9) stock reacts to monetary easing2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Using data filters to optimize entry into Exelixis Inc.July 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction - Investing.com Nigeria
Why Exelixis Inc. is moving todayMarket Trend Summary & Daily Momentum Trading Reports - newser.com
Why Exelixis Inc. stock could benefit from AI revolutionEarnings Beat & AI Optimized Trade Strategies - newser.com
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Analyst Calls & Growth Focused Entry Reports - newser.com
How Exelixis Inc. stock trades during market volatilityQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Will Exelixis Inc. benefit from macro trends2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction By Investing.com - Investing.com South Africa
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth By Investing.com - Investing.com Philippines
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth - Investing.com
Key metrics from Exelixis Inc.’s quarterly data2025 Price Targets & AI Optimized Trading Strategy Guides - newser.com
Is Exelixis Inc. stock cheap at current valuation2025 Geopolitical Influence & Community Consensus Trade Signals - newser.com
What recovery options are there for Exelixis Inc.Quarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
Exelixis Inc expected to post earnings of 61 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL) - The Globe and Mail
Exelixis Inc Stock Analysis and ForecastStock Market Trends & Small Investment Growth Plans - earlytimes.in
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data - AOL.com
Using RSI to spot recovery in Exelixis Inc.Layoff News & Weekly Momentum Stock Picks - newser.com
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewswire Inc.
Best data tools to analyze Exelixis Inc. stock2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):